Antibiotic prescribing in telehealth can be appropriate with guidance, study finds
Telemedicine visits in Brazil performed under rigorous adherence to antibiotic stewardship guidelines were associated with appropriate antibiotic prescribing for patients with low-risk conditions, Brazilian and Australian researchers reported yesterday in the International Journal of Infectious Diseases.
While some studies have suggested that antibiotic prescribing rates for people who consult telemedicine services may be higher than those who have face-to-face visits with providers, most of these studies have not specified the protocols and guidelines accessible to providers or how telemedicine providers should be trained and monitored for antibiotic stewardship.
In this study, researchers assessed antibiotic prescribing at a hospital in Sao Paulo, where all telemedicine providers were required to be trained on international antibiotic stewardship protocols based on the best current evidence, and senior supervisors monitored prescription rates.
The study included all patients 18 and older who sought telemedicine consultations for acute but non-urgent symptoms through the hospital from January 2019 through February 2020. Diseases for which an antibiotic might be required were classified into five diagnostic groups: upper respiratory tract infection (URI), acute pharyngotonsillitis (PT), acute sinusitis (AS), urinary tract infection (UTI), and acute diarrhea (AD).
Of the 2,328 patients included, 2,085 (89.6%) received telemedicine consultations alone, and 243 (10.4%) were referred for face-to-face consultation. Among the telemedicine patients, 472 (22.6%) received an antibiotic. The antibiotic prescribing rates per diagnostic group were 2.5% for URI, 35% for PT, 51.8% for AS, 1.6% for UTI, and 1.6% for AD. In most cases, these prescriptions were in line with international stewardship protocols, and the prescribing rates were low compared with other telemedicine programs, the authors concluded.
"This study shows that using technology and proper antibiotic stewardship may mitigate the apprehension that video visits may lead to a high antibiotic prescription rate," they wrote.
Feb 9 Int J Infect Dis abstract
Macrolide resistance found in 40% of US Strep pneumoniae isolates
A surveillance study published last week in Open Forum Infectious Diseases found macrolide resistance in 40% of Streptococcus pneumoniae isolates from adult ambulatory and inpatient settings in US hospitals.
Using microbiology laboratory data from the BD (Becton, Dickinson and Company) Insights Research Database, researchers evaluated S pneumoniae blood or respiratory cultures with antibiotic susceptibility test results collected at 329 US hospitals from October 2018 through September 2019. The pathogen is the most common bacterial cause of community-acquired pneumonia (CAP), an illness that results in more than 1 million emergency department visits and an estimated 750,000 to 1 million hospitalizations annually.
Isolates with resistance to azithromycin, clarithromycin, or erythromycin were considered macrolide-resistant. The researchers used US Census geographic regions and ZIP code tabulation areas to determine the regional distribution of resistant isolates.
The overall rate of macrolide resistance among 3,626 S pneumoniae isolates analyzed was 39.5%, with a significantly higher resistance rate found in respiratory isolates (47.3%) than in blood isolates (29.6%). Isolates from ambulatory settings had a higher rate of resistance than isolates from inpatients (45.3% vs 37.8%).
Evaluation of regional resistance found the highest rate of macrolide resistance in the West North Central region (54.2%), followed by the South Atlantic (48.0%). Although geographic variations were observed, most regions had overall macrolide resistance rates higher than 25%, and more than 25% of respiratory isolates in all regions were macrolide-resistant.
The authors say the results, along with other recent US or North American studies showing high macrolide resistance in S pneumoniae, may explain recent findings of high failure rates (21%) with macrolide monotherapy in patients with CAP. They say ongoing surveillance efforts are needed to track resistance trends in S pneumoniae and suggest that clinicians in most parts of the country consider alternatives to macrolide monotherapy as empiric therapy for suspected CAP.
Feb 4 Open Forum Infect Dis abstract
Officials confirm 4 more MERS cases in Saudi Arabia, 2 fatal
Saudi Arabia's health ministry reported four new MERS-CoV cases in four areas since the start of the new year, two of which were fatal, according to three recently posted weekly updates.
The first MERS-CoV (Middle East respiratory syndrome coronavirus) case involves a 63-year-old man from the city of Al Ju'ranah in Mecca province in the west. The man died of his infection, initially recorded on Jan 19, and the investigation didn't reveal any contact with camels. The source of the virus is listed as primary, meaning he likely didn't contract the virus from another known case-patient.
Also, the Saudi Ministry of Health (MOH) reported a second fatal case that was initially reported on Feb 2, involving a 48-year-old man from the city of Rabigh, located north of Jeddah in western Saudi Arabia on the Red Sea coast. His exposure is also listed as primary, and no history of contact with camels was found.
The other cases were reported on Feb 7 and Feb 9. The first patient is an 84-year-old man from Riyadh who had contact with camels, and the second is a 46-year-old man from Al Ahsa in eastern Saudi Arabia who also had contact with camels.
Earlier this month, the World Health Organization said in a snapshot of MERS activity in the last half of 2020 that, since 2012, 2,566 cases have been reported in humans, at least 882 of them fatal.
Saudi MOH epi week 3 report
Saudi MOH epi week 5 report
Saudi MOH epi week 6 report
Feb 1 CIDRAP News scan
Lower-dose intradermal flu vaccine possible alternatives to standard shots
A meta-analysis published yesterday in JAMA Network Open suggests reduced-dose intradermal flu vaccines could be a reasonable alternative to standard-dose intramuscular vaccines (the typical flu shot), and could be used as a dose-sparing strategy if needed for seasonal flu vaccination campaigns.
The study reviewed 30 completed studies that included a total of 177,780 participants. The authors found seroconversion rates of low doses of intradermal influenza vaccine compared with the standard intramuscular dose for each of the H1N1, H3N2, and B strains were not statistically significantly different.
"There was no statistically significant difference in seroconversion rates between the 3-µg, 6-µg, 7.5-µg, and 9-µg intradermal vaccine doses and the 15-µg intramuscular vaccine dose for each of the H1N1, H3N2, and B strains, but rates were significantly higher with the 15-µg intradermal dose compared with the 15-µg intramuscular dose for the H1N1 strain," the authors wrote.
The authors said their findings, which reflected vaccine immune response but not protection from contracting influenza, were important in light of the development of COVID-19 vaccines, and suggested intradermal needles could be a useful tool to improve vaccine acceptance.
"The development of novel intradermal vaccine delivery systems, such as self-administrable patches with coated microprojections or biodegradable needles, could potentially improve vaccine acceptance and uptake," the authors concluded.
Feb 9 JAMA Netw Open study